Patents Examined by Carlos Azpuru
  • Patent number: 11617814
    Abstract: Described herein are polymeric particles configured for intravascular delivery of pharmaceutical agents, e.g., to a diseased site, and methods of forming and using same. Preparation of these polymer particles is also described.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: April 4, 2023
    Assignee: Terumo Corporation
    Inventors: Gregory M. Cruise, Xinping Wu, Gloria Hincapie, Yue Wu
  • Patent number: 11617792
    Abstract: The invention relates to pharmaceutical compositions in liquid form comprising pradofloxacin in an aqueous solution and citric acid or thioglycerol as antioxidants.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: April 4, 2023
    Assignee: Bayer Animal Health GmbH
    Inventors: Iris Heep, Patrick Billian
  • Patent number: 11617743
    Abstract: Provided herein are pharmaceutical formularions comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: April 4, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Rebecca J. Abergel, Taylor A. Choi, Kenneth N. Raymond, David K. Shuh
  • Patent number: 11607388
    Abstract: Drug-loaded microbead compositions include microbeads of a water-swellable polymer material and a complex of a carrier and a therapeutic agent chemically bonded to the carrier. The complex is embedded in the polymer material. The therapeutic agent is not chemically bonded to the water-swellable polymer material. The drug-loaded microbead composition has a water content of less than 1% by weight, based on the total weight of the drug-loaded microbead composition. The drug-loaded microbead composition may be rehydrated to form an embolization composition for use in in embolization therapy. Methods for preparing the drug-loaded microbead compositions and the embolization compositions include loading a therapeutic agent into a water-swellable polymer material to form microbeads, then removing water from the microbeads.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: March 21, 2023
    Assignee: C.R. Bard, Inc.
    Inventors: Hiep Do, Michael Randall
  • Patent number: 11602565
    Abstract: An anti-caking or flow agent is provided herein. The anti-caking or flow agent may include a bamboo extract that may include silica and carbohydrate. The bamboo extract may have a loose density (g/ml) of from about 0.14 g/ml to about 0.18 g/ml or a tapped density (g/ml) of from about 0.18 g/ml to about 0.22 g/ml. The bamboo extract may also include particles of the silica and the carbohydrate, wherein the particles have a size (Dv50) of from about 35 ?m to about 55 ?m. This anti-caking or flow agent may facilitate the manufacture, packaging, or storage of dry powdered food ingredients and food products such as spices, flavorings, and powdered food mixes as well as pharmaceuticals and nutraceuticals.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: March 14, 2023
    Assignee: Griffith Foods International, Inc.
    Inventors: Gregory J. Meyers, Samantha L. Amos
  • Patent number: 11590080
    Abstract: Drug-loaded microbead compositions include microbeads of a biodegradable material and vesicular agents located within or associated with the biodegradable material of the microbeads. The vesicular agents include a lipid bilayer and comprise liposomes or ethosomes. The drug-loaded microbeads include a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents. Drug-loaded biodegradable microbead compositions include microbeads of biodegradable material and a therapeutic agent.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: February 28, 2023
    Assignee: C.R. Bard, Inc.
    Inventors: Elena Afonina, Hiep Do, Emily Goel, Oleg Guryev, Cyal Lecy, Majid Mehrpouyan, Michael Randall, Marybeth Sharkey, Jeffrey Wang
  • Patent number: 11583510
    Abstract: Provided herein are methods of administering a once-nightly dosage of gamma-hydroxybutyrate after a high-fat meal.
    Type: Grant
    Filed: February 7, 2022
    Date of Patent: February 21, 2023
    Assignee: Flamel Ireland Limited
    Inventors: Julien Grassot, David Monteith, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • Patent number: 11583539
    Abstract: Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: February 21, 2023
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Jan Mattsson, Pat Horn, Paresh Soni
  • Patent number: 11583578
    Abstract: The invention relates to pharmaceutical compositions comprising at least one antigen and an adjuvant composition, where the adjuvant composition comprises a saponin and a liposome. The liposome of the composition comprises monophosphoryl lipid A (MPLA), cholesterol and a phospholipid that is in a liquid crystalline state at greater than or equal to 23° C., and the concentration of cholesterol to lipid in the liposome is greater than 50% (mol/mol). The antigen in the composition is a soluble Plasmodium falciparum recombinant circumsporozoite protein (rCSP) comprising the amino acid sequence of SEQ ID NO:1, or a P. falciparum rCSP peptide that is at least 95% identical to the amino acid sequence of SEQ ID NO:1.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: February 21, 2023
    Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government Of The United States, As Represented By The Secretary Of The Army
    Inventors: Sheetij Dutta, Zoltan Beck, Carl Alving, Gary Matyas
  • Patent number: 11571402
    Abstract: The present disclosure relates to dispersible pharmaceutical compositions comprising N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: February 7, 2023
    Assignee: SpringWorks Therapeutics, Inc.
    Inventors: Kristin Patterson, Jiping Liu
  • Patent number: 11571438
    Abstract: The present invention discloses a nutraceutical composition for up-regulation of SIRT 1 expression. The nutraceutical composition comprises NMN at in an amount between 300 mg and 500 mg, in an amount of 500 mg, and a soluble agent. The NMN and polyphenol are wrapped in a soluble agent as a protective bio-active agent to increase bioavailability and protect the polyphenol compounds during gut absorption. The invention also discloses a method of preparing a nutraceutical composition by weighing polyphenol at a suitable concentration, mixing the polyphenol with a suitable soluble agent and finally adding NMN to the mixture and blended it to form the nutraceutical composition. The nutraceutical composition up regulates SIRT1 and hence is suitable for treatment of various diseases and used in the form of powder, liquid, tablets, capsules, chewable form, gels, etc.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: February 7, 2023
    Inventors: Sasan Akhavan, Amir Hayeri
  • Patent number: 11564834
    Abstract: The present invention provides a drug composition comprising particles comprising a biodegradable or bioerodable polymer and a drug, a soluble, biodegradable or bioerodible excipient, a bulking agent and a reconstitution aid. The invention also provides a pharmaceutical formulation and a unit dosage form of the pharmaceutical formulation. The invention provides methods of treatment of a disease or condition accordingly. The invention also provides a drug composition for use in a cannulation device.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: January 31, 2023
    Assignee: Oxular Limited
    Inventors: Robert Steven Bley, Stanley R. Conston, Ronald K. Yamamoto, Tien T. Nguyen, John P. Lunsford, Dillon Daniel Martinez, Loc X. Phan
  • Patent number: 11559578
    Abstract: A method for formation of a vaccine comprising combining a cationic polymer adjuvant with an antigen to form first immunoparticles through charge interactions and producing a treatment formulation for the vaccine comprising the first immunoparticles.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: January 24, 2023
    Assignee: International Business Machines Corporation
    Inventors: James L. Hedrick, Yi Yan Yang, Ashlynn Lee, Chuan Yang
  • Patent number: 11547775
    Abstract: The invention relates to an arrangement (1) comprising at least one structural element (2) made of an absorbable material with an antibacterial effect with a mount, which possesses an aspect ratio greater than 10 and whereat the material is a rapidly corroding magnesium alloy. The invention further relates to a mount (10) with an arrangement (1) carried by the mount (10) comprising at least one structural element (2) made of an absorbable material with an antibacterial effect.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 10, 2023
    Assignee: Meotec GmbH & Co. KG
    Inventors: Alexander Kopp, Francesco D'Elia, Ralf Smeets
  • Patent number: 11547776
    Abstract: The present invention provides porous biomimetic scaffolds and methods for making the same. The scaffolds have graded pore sizes for enhanced cell penetration. The scaffolds are useful for wound regeneration by facilitating cell penetration into the scaffold interior and due to their inherent immunomodulatory effects. The scaffolds have tissue modeling specification by mimicking the inherent stratified structure of certain tissues.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: January 10, 2023
    Assignee: Temple University-Of The Commonwealth System of Higher Education
    Inventors: Azadeh Timnak, Peter I. Lelkes, Yah-el H. Har-el
  • Patent number: 11541073
    Abstract: The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: January 3, 2023
    Assignee: Children's Hospital Medical Center
    Inventors: David A. Hildeman, Andrew Herr, Suhas G. Kallapur, Jarek Meller, Alexander Thorman
  • Patent number: 11534396
    Abstract: This invention relates to methods of treatment with a sustained release biodegradable ocular implant containing a tyrosine inhibitor dispersed in a hydrogel.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: December 27, 2022
    Assignee: Ocular Therapeutix, Inc.
    Inventors: Charles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
  • Patent number: 11530132
    Abstract: A composition includes porous silica particles to carry a cell fate modulating factor therein. A method for modulating cell fate includes treating various cells with the composition. The cell fate modulating factor is delivered to a stable target receptor, toxicity to subject cells for delivery may be reduced, a fate of the subject cells can be controlled through sustained release of at least 99 wt. % of the cell fate modulating factor.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: December 20, 2022
    Assignee: LEMONEX INC.
    Inventors: Dal-Hee Min, Cheolhee Won, Sejin Park, Seongchan Kim
  • Patent number: 11524014
    Abstract: The present disclosure is directed formulations, delivery systems and/or methods of use that have a novel a sustained release multi-phasic concentration pattern that may be used, among other things, for reducing mammographic breast density and/or breast stiffness in warm-blooded animals. For example, the formulation may comprise: the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor to a subject that provides a sustained release multi-phasic concentration pattern in the blood of the subject over time as measured by serum concentration for the androgen and plasma concentration for the aromatase inhibitor and improves, among other things, breast tissue stabilization and/or increases of the levels of androgen receptor expression.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: December 13, 2022
    Assignee: Havah Therapeutics Pty Ltd.
    Inventor: Stephen Nigel Birrell
  • Patent number: 11517650
    Abstract: Methods for applying a coating to a surface of a substrate for inhibition and prevention of implant-associated complications (including implant-associated infections), methods for inhibiting and preventing implant-associated complications (including implant-associated infections), implant-associated infection inhibiting coatings, and coated devices are provided. Coating processes include a) providing a saturated or supersaturated solution of an antibiotic in a fast-evaporating or medium-evaporating organic solvent; b) coating the surface of the substrate with at least one application of solution, each application followed directly by a solvent evaporation period.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: December 6, 2022
    Assignee: University of Cincinnati
    Inventors: Aaron Seitz, Michael Edwards, Erich Gulbins, Ryan Gobble